BioNTech SE (BNTX) Income towards Parent Company (2018 - 2025)
BioNTech SE (BNTX) reported Income towards Parent Company of -$174.4 million for Q4 2025, down 147.59% on a YoY basis from $366.4 million in Q4 2024, and down 290.98% sequentially from $91.3 million in Q3 2025.
BioNTech SE (BNTX) Income towards Parent Company (2018 - 2025) Analysis & Trends
BioNTech SE (BNTX) has 8 years of Income towards Parent Company data on file, last reported at -$174.4 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 147.59% year-over-year to -$174.4 million; the trailing twelve-month figure through Dec 2025 stood at -$1.1 billion (down 41.52% YoY), and the FY2025 full-year result was -$1.1 billion, down 47.92% from the prior year.
- Income towards Parent Company slipped to -$174.4 million in Q4 2025, from $91.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $7.2 billion in Q3 2021 to a low of -$865.6 million in Q2 2024.
- A 5-year average of $1.7 billion and a median of $343.3 million in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 1512953662792.27% in 2021 and tumbled 147.59% in 2025, its largest moves.
- Tracing BNTX's Income towards Parent Company over 5 years: stood at $3622.0 in 2021, then surged by 114544050.96% to $4.1 billion in 2022, then plunged by 77.48% to $934.5 million in 2023, then sank by 60.79% to $366.4 million in 2024, then plunged by 147.59% to -$174.4 million in 2025.
- Business Quant data shows BNTX's Income towards Parent Company at -$174.4 million in Q4 2025, $91.3 million in Q3 2025, and -$474.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | BioNTech SE | 22.06 Bn | 4.75 Bn | 668.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -174.37 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -474.06 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 366.42 Mn |
| Sep 30, 2024 | 131.02 Mn |
| Jun 30, 2024 | -865.60 Mn |
| Mar 31, 2024 | -378.60 Mn |
| Dec 31, 2023 | 934.45 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -690.38 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 3,622.04 |
| Sep 30, 2021 | 7.22 Bn |
| Jun 30, 2021 | 6.33 Bn |
| Mar 31, 2021 | 2.60 Bn |